Crisaborole ointment for skin issues caused by cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial investigates the effectiveness and safety of crisaborole ointment in patients with metastatic colorectal cancer experiencing skin toxicity due to cetuximab treatment. The study will enroll 33 participants who will apply the ointment twice daily for 12 weeks. The primary focus is on alleviating acneiform eruptions, a common side effect that can significantly impact patients' quality of life and treatment adherence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosed mCRC and undergoing Cetuximab treatment;
2. ≥2 grade EGFR inhibitor-related acneiform eruption, evaluated by National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE）5.0;
3. Age 18 years and older；
4. ECOG performance status 0-2.；
5. Bone marrow ,brain, heart, kidney and other organ function well;；
6. Expected survival time more than 3 months;

Exclusion Criteria:

1. The presence of any active skin disease；
2. Undergoing any current hormone therapy for any other disease;
3. Prior allergic reaction or severe intolerance to crisaborole ointment

Where it's running

• WeiWei Xiao
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Weiwei Xiao — Sun Yat-sen University
• Study coordinator: Weiwei Xiao
• Email: xiaoww@sysucc.org.cn
• Phone: +8613710390520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cetuximab bioequivalence test in healthy men

  This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.

  Recruiting Phase 1 HC Biopharma Inc. · Haikou, Hainan · NCT07813468

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Sintilimab + ipilimumab N01 with cetuximab and dabrafenib for MSS BRAF V600E metastatic colorectal cancer

  This trial will test whether combining the immunotherapies sintilimab and ipilimumab N01 with cetuximab and dabrafenib helps people with microsatellite-stable, BRAF V600E metastatic colorectal cancer live longer or have better tumor control.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07506109

• Cetuximab beta plus fruquintinib, with or without immunotherapy, for first-line treatment of RAS/BRAF wild‑type unresectable metastatic colorectal cancer

  This trial tests whether combining cetuximab beta and fruquintinib, with or without immune checkpoint inhibitors, can control cancer as a chemotherapy‑free first‑line option for patients with RAS/BRAF wild‑type unresectable metastatic colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07257653

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination of treatments for advanced colorectal cancer to see if it can help patients live longer and feel better.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT06776757

• Combination treatment for advanced colorectal cancer with specific mutations

  This study is testing a combination of three drugs to see if they can help people with advanced colorectal cancer that has specific mutations after they've already tried other treatments.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT06412198

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.